FDA authorizes use of bivalent mRNA COVID-19 vaccines, monovalent rescinded

SILVER SPRING, MD, April 18, 2023—The U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals. This action includes authorizing the current bivalent vaccines (original and omicron BA.4/BA.5 strains) to be used for all doses administered […]